Skip to main content
You're viewing the free public version. Create a free account for full research and member tools. Join free

B Vitamins Slow Alzheimer’s Brain Atrophy 7-Fold

GMI Research Group
by GMI Research Group
· Published Feb 08, 2024 · 2 min read · Sources
0:00 / 0:00
0:00 / 0:00

Sign in to access this feature

Create a free account or sign in to use AI summaries, listen to articles, download PDFs, and save to your library.

12,605 views
Share:

This article is copyrighted by GreenMedInfo LLC, 2024

Visit our Re-post guidelines

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of GreenMedInfo or its staff.

B Vitamins Slow Alzheimer’s Brain Atrophy 7-Fold

Amid a devastating epidemic stealing minds and memories, a new study suggests an astonishing 7-fold reduction in Alzheimer's brain atrophy from a shockingly simple treatment: high-dose B vitamins.

With over 6 million Americans living with Alzheimer's disease and no FDA-approved treatments that effectively slow its progression, there is a desperate need for new therapeutic strategies.1 Despite billions invested in developing medications targeting Alzheimer's brain plaques and tangles, drug trial after drug trial has ended in disappointment.2 But an unlikely natural treatment - high doses of three humble B vitamins - may succeed where these drugs have failed. 

A groundbreaking new study published in the Proceedings of the National Academy of Sciences (Douaud et al., 2013)3 suggests that high-dose B vitamin treatment could slow the progression of Alzheimer's disease by as much as 7-fold. The double-blind randomized controlled trial included 156 elderly patients with mild cognitive impairment (MCI)4, an early Alzheimer's risk state. Patients who took supplements of folic acid, vitamins B6 and B12 over two years had dramatically less brain atrophy detected via MRI scans compared to patients taking a placebo. Critically, the treatment was most effective in patients with elevated homocysteine levels.5 By lowering this amino acid, B vitamins reduced grey matter loss in brain regions vulnerable in Alzheimer's.6  

The results provide a glimmer of hope amid the litany of failed Alzheimer's clinical trials.7 Unlike risky experimental drugs designed to remove plaques or tangles, vitamin B supplements are safe, natural, and already indicated for high homocysteine levels. If these unprecedented findings are confirmed in ongoing trials, vitamin supplementation could offer the first major advancement in Alzheimer's treatment in over 15 years.8 With cases expected to triple in coming decades, this affordable regimen could have tremendous potential to alleviate the staggering burden of this epidemic.9

For more research on the therapeutic value of B vitamins and other strategies for Alzheimer's disease, consult our database with over 10,000 distinct topics: www.greenmedinfo.com.

GMI Research Group

GMI Research Group

The GMI Research Group (GMIRG) is dedicated to investigating the most important health and environmental issues of the day.  Special emphasis will be placed on environmental health.  Our focused and deep research will explore the many ways in which the present condition of the human body directly reflects the true state of the ambient environment.

Read More from This Author

Sign in to follow authors

Create a free account or sign in to follow your favorite authors and keep up with their latest work.

Share:

References

1. Alzheimer's Association. 2022 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia 2022; 18. 

2. Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2017. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017; 3: 367-384.

3. Douaud et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proceedings of the National Academy of Sciences Jun 2013, 110 (23) 9523-9528.

4. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of internal medicine 2004; 256:183-194.

5. Smith AD, Refsum H. Homocysteine, B Vitamins, and Cognitive Impairment. Annual review of nutrition 2016; 36:211-239. 

6. Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proceedings of the National Academy of Sciences Jun 2013, 110 (23) 9523-9528.

7. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's research & therapy 2014; 6: 37.

8. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. The Lancet Neurology 2010; 9: 702-716.

9. Alzheimer's Association. Changing the Trajectory of Alzheimer's Disease: A National Imperative. Alzheimer's Association 2010.

Comments

Sign in or create a free account to join the conversation.

Sign in to comment

Be the first to comment.

Trusted By Professionals and Teams:

The National Health Federation
Stand For Health Freedom
Global Healing Institute
Global Wellness Forum
MAHA Action
Myers Detox
Natural News
Mercola.com

Unlock Evidence-Based Health Research

Join 500,000+ members accessing 10,000+ natural health topics.

Subscribe to our informative Newsletter & Receive

Cancer Fighting Foods Ebook

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of GreenMedInfo or its staff.